MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

For reference, Novo Nordisk also offers a highly successful weight loss drug, Wegovy, a GLP-1 receptor agonist.

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...